Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 8c

Seattle Genetics Inc. (NASDAQ: SGEN) reported Q1 EPS of ($0.13), $0.08 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $68.3 million versus the consensus estimate of $64.62 million.

“Our financial and business results to date in 2014 reflect continued progress across our top three corporate priorities of building ADCETRIS into a major global brand, advancing our robust ADC pipeline and enhancing our leadership position in the field of ADCs,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. “ADCETRIS is now commercially available in 40 countries and is being evaluated in more than 30 clinical trials. We are also advancing five other clinical-stage ADCs towards our goal of identifying additional product candidates. And, the breadth of data presented at the recent AACR annual meeting underscores our continued innovation in the field of ADCs and the progress both we and our collaborators are making with programs using our proprietary technology.”

For earnings history and earnings-related data on Seattle Genetics Inc. (SGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c